Clinical potential of cariprazine in the treatment of acute mania

Psychiatria Danubina

Volumn 25, Issue 3, 2013, Pages 207-213

  Altmbas, Kürat ^a   Guloksuz, Sinan ^b,c   Oral, Esat Timuçin ^d  

^a ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ISTANBUL COMMERCE UNIVERSITY   (Turkey)

Author keywords

Antipsychotic; Bipolar disorder; Cariprazine; Mania; Psychopharmacology

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARIPRAZINE; CLOZAPINE; CYTOCHROME P450 3A4; DINORCARIPRAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRUG METABOLITE; HALOPERIDOL; NEUROLEPTIC AGENT; NORCARIPRAZINE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; UNCLASSIFIED DRUG; ZIPRASIDONE;

AKATHISIA; BINDING AFFINITY; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CONSTIPATION; CORPUS STRIATUM; DIABETES MELLITUS; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LEARNING; LOW DRUG DOSE; MANIA; METABOLIC DISORDER; METABOLIC SYNDROME X; NAUSEA; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ACUTE DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERAZINES;

EID: 84885234331     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, et al.: A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996; 93:1945-9.
2. Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keser GM, et al: Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett 2012; 22:3437-40.
3. Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC: Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis. Paediatr Drugs 2013; 15:139-50.
4. Altnba K, Smith DJ & Craddock N: Rediscovering the Bipolar Spectrum. Archives of Neuropsychiatry 2011; 48:167-70.
5. American Psychiatric Association (APA): Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Press, 2000.
6. Assié MB, Cosi C & Koek W: 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 1997; 334:141-7.
7. Auclair AL, Cathala A, Sarrazin F, Depoortére R, Piazza PV, Newman-Tancredi A, et al.: The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 2010; 114:1323-32.
8. Awad AG & Voruganti LN: New antipsychotics, compliance, quality of life, and subjective tolerability-Are patients better off? Can J Psychiatry 2004a; 49:297-302.
9. Awad AG & Voruganti LN: Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004b; 18:877-93.
10. Baldessarini RJ & Tarazi FI: Pharmacotherapy of psychosis and mania. In Brunton LL, Lazo JS & Parker KL (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics, (11th ed), 461-500. McGraw-Hill, 2005.
11. Bose A, Li D, Migliore R, Werner P, Nemeth G & Laszlovsky I: The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia Int J Neuropsychopharmacol 2011; 26(suppl 1):S1354.
12. Breier A, Meehan K, Birkett M, David S, Ferchland I & Sutton V: A double-blind, placebo-controlled doseresponse comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59:441-8.
13. Bruins Slot LA, Kleven MS & Newman-Tancredi A: Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 2005; 49:996-1006.
14. Caccia S: Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol 2011; 7:829-46.
15. Chou JC, Zito JM, Vitrai J, Craig TJ, Allingham BH & Czobor P: Neuroleptics in acute mania: a pharmacoepidemiologic study. Ann Pharmacother 1996; 30:1396-8.
16. Chue P: The relationship between patient satisfaction and treatment outcomes in schizophrenia. Psychopharmacol 2006; 20(Suppl 6):38-56.
17. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al.: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-Analysis. Lancet 2011; 378:1306-15.
18. Citrome L: Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9:193-206.
19. Correll CU, Frederickson AM, Kane JM & Manu P: Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008; 10:788-97.
20. DeLeon A, Patel NC & Crismon ML: Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Therap 2004; 26:649-66.
21. Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, et al.: Serotonin 5-HT2B receptors are required for 3,4 methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 2008; 28:2933-40.
22. Fountoulakis KN, Vieta E: Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009; 8:16.
23. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, et al.: Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007; 6:27.
24. Gründer G, Hiemke C, Paulzen M, Veselinovic T & Vernaleken I: Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 2011; 44:236-48.
25. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE & Joyce JN: Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997; 54:225-32.
26. Gyertyán I & Sághy K: The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007; 572:171-4.
27. Gyertyán I & Sághy K: Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav Pharmacol 2004; 15:253-62.
28. Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, et al.: Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 2008; 378:529-39.
29. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, et al.: Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 2011; 59:925-35.
30. Heusler P, Newman-Tancredi A, Loock T & Cussac D: Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol. 2008; 581:37-46.
31. Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA & Frye MA: Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64:53-9.
32. Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, et al.: Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006; 86:138-46.
33. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA & Meltzer HY: 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5- HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76:1521-31.
34. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079-87.
35. Joyce JN & Millan MJ: Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005; 10:917-25.
36. Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al.: Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo- controlled study. J Clin Psychiatry 2012; 73:617-24.
37. Kapur S & Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1081-1090.
38. Kapur S & Seeman P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158:360-9.
39. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al.: Effects of olanzapine, quetiapine and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164:1061-71.
40. Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG, et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013; 2:CD006569.
41. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al.: Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333:328-40.
42. Knesevich MA, Papadakis K, Bose A, Papadakis K, Starace A, Thomson L, et al.: Phase II Trial of Cariprazine in Acute Mania Associated with Bipolar I Disorder: Effect across Symptoms 49th Annual NCDEU Meeting; 2009 June 29- July 2; Florida, USA.
43. Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'italien GJ, et al.: Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring) 2008; 16:749-54.
44. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S: Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011; 1:CD006626.
45. Laszlovszky I, Gage A, Kapas M & Ghahramani P: Characterization of cariprazine (RGH-188) D3/D2 receptoroccupancy in healthy volunteers and schizophrenic patients by positron emission tomography (PET). European Psychiatry 2010; 25(suppl 1):S1616.
46. Markowitz JS, Brown CS & Moore TR: Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33:73-85.
47. McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN & Wilson AA: The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2- selective ex vivo but not in vitro. Neuropsychopharmacology 2010; 35:1826-35.
48. Meltzer HY, Li Z, Kaneda Y & Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol Psychiatry 2003; 27:1159-72.
49. Michalak EE, Yatham LN & Lam RW: Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes 2005; 3:72.
50. Moteshafi H & Stip E: Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-Analysis. Expert Opin Drug Saf 2012; 11:713-32.
51. Newman-Tancredi A & Kleven MS: Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011; 216:451-73.
52. Oral TE: Treatment of acute mania. Neuro Endocrinol Lett 2005; 26(suppl1):9.
53. Robb JC, Cooke RG, Devins GM, Young LT & Joffe RT: Quality of life and lifestyle disruption in euthymic bipolar disorder. J Psychiatr Res 1997; 31:509-17.
54. Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E & Ayuso-Mateos JL: Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009; 78:285-97.
55. Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, et al.: Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl) 2011; 218:579-87.
56. Starace A: Cariprazine in the Treatment of Acute Mania in Bipolar Disorder: A Double-Blind, Placebo- Controlled Phase III Trial. Proceedings of the 165th Annual Meeting of the American Psychiatric Association; 2012 May 5- 9; Philadelphia, USA.
57. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al.: Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr Res 2013; 145:116-9.
58. Tarr GP, Glue P & Herbison P: Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania-A systematic review and meta-Analysis. J Affect Disord 2011; 134:14-19.
59. Tohen M, Hennen J, Zarate CM Jr, Baldessarini RJ, Strakowski SM & Stoll AL: Two 20 year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157: 220-8.
60. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C & Sanger T: A meta-Analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001; 65:85-93.
61. Tomida K, Takahashi N, Saito S, Maeno N, Iwamoto K, Yoshida K, et al.: Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci 2010; 64:62-9.
62. Yen CF, Cheng CP, Huang CF, Yen JY, Ko CH & Chen CS: Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Disord 2008; 10:617-24.
63. Yildiz A, Vieta E, Leucht S & Baldessarini RJ: Efficacy of Antimanic Treatments: Meta-Analysis of Randomized, Controlled Trials. Neuropsychopharmacology 2011; 36:375-89.
64. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al.: Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98:247-52.
65. Zarate CA, Jr & Tohen M: Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. J Clin Psychiatry 2000; 61:33-8.
66. Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N & Schmauss C: Cariprazine, a dopamine D(3)-receptorpreferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 2012; 226:91-100.